- Home
- MRSN vs ACRV Comparison
MRSN vs ACRV Comparison
Compare MRSN & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- ACRV
- Stock Information
- Founded
- MRSN 2001
- ACRV 2018
- Country
- MRSN United States
- ACRV United States
- Employees
- MRSN N/A
- ACRV 78
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- MRSN Health Care
- ACRV Health Care
- Exchange
- MRSN Nasdaq
- ACRV Nasdaq
- Market Cap
- MRSN 40.7M
- ACRV 34.5M
- IPO Year
- MRSN 2017
- ACRV 2022
- Fundamental
- Price
- MRSN $0.37
- ACRV $1.11
- Analyst Decision
- MRSN Strong Buy
- ACRV Buy
- Analyst Count
- MRSN 5
- ACRV 7
- Target Price
- MRSN $5.75
- ACRV $17.60
- AVG Volume (30 Days)
- MRSN 3.1M
- ACRV 728.6K
- Earning Date
- MRSN 05-15-2025
- ACRV 05-14-2025
- Dividend Yield
- MRSN N/A
- ACRV N/A
- EPS Growth
- MRSN N/A
- ACRV N/A
- EPS
- MRSN N/A
- ACRV N/A
- Revenue
- MRSN $34,006,000.00
- ACRV N/A
- Revenue This Year
- MRSN N/A
- ACRV N/A
- Revenue Next Year
- MRSN N/A
- ACRV N/A
- P/E Ratio
- MRSN N/A
- ACRV N/A
- Revenue Growth
- MRSN N/A
- ACRV N/A
- 52 Week Low
- MRSN $0.26
- ACRV $1.05
- 52 Week High
- MRSN $2.83
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- MRSN 51.71
- ACRV 35.20
- Support Level
- MRSN $0.33
- ACRV $1.06
- Resistance Level
- MRSN $0.38
- ACRV $1.19
- Average True Range (ATR)
- MRSN 0.04
- ACRV 0.09
- MACD
- MRSN 0.00
- ACRV 0.05
- Stochastic Oscillator
- MRSN 58.60
- ACRV 23.53
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.